Patents Examined by Elly-Gerald Stoica
  • Patent number: 11993637
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: May 28, 2024
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Patent number: 11987612
    Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: May 21, 2024
    Assignee: Alector LLC
    Inventors: Spencer Liang, Samuel Nalle, Jeonghoon Sun, Hua Long, Rashmi Bankoti
  • Patent number: 11980657
    Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: May 14, 2024
    Assignee: AFFIRIS CVD GMBH
    Inventors: Sylvia Brunner, Gergana Galabova, Gabriele Winsauer, Erika Bilcikova, Claudia Juno, Pola Linzmayer-Hirt, Birgit Schuh, Guenther Staffler
  • Patent number: 11965025
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: April 23, 2024
    Assignee: Marengo Therapeutics, Inc.
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
  • Patent number: 11958901
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 16, 2024
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
  • Patent number: 11957695
    Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 16, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Patent number: 11931423
    Abstract: Bioconjugates and methods of making bioconjugates are provided, wherein the bioconjugates comprise glucose oxidase and nanoparticles that can kill tumor cells. For example, glucose oxidase-iron oxide bioconjugates can produce reactive oxygen species from blood glucose, causing cell death. The use of superparamagnetic iron oxide nanoparticles can provide magnetic resonance imaging guidance to facilitate imaging-guided drug delivery and combine diagnostics with therapy.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 19, 2024
    Inventors: Dexing Zeng, Di Gao, Jiamin Wu
  • Patent number: 11931417
    Abstract: Methods are provided for producing a PEGylated interleukin 11 (IL-11) by treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: March 19, 2024
    Assignee: Nansha Biologics (Hong Kong) Limited
    Inventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
  • Patent number: 11932696
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 19, 2024
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Patent number: 11920135
    Abstract: Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: March 5, 2024
    Assignee: University of Massachusetts
    Inventors: Hira Lal Goel, Arthur M. Mercurio
  • Patent number: 11897950
    Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 13, 2024
    Assignees: Augusta University Research Institute, Inc., Department of Veterans Affairs
    Inventors: Kebin Liu, John Klement, Priscilla S. Redd
  • Patent number: 11896648
    Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: February 13, 2024
    Inventors: Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
  • Patent number: 11890302
    Abstract: The present invention relates to gamma delta (??) T cells and/or Natural Killer (NK) cells expressing constructs to provide for the expression of a Chimeric Antigen Receptor (CAR) incorporating the signalling domain of FCY Receptors. Suitably the invention also relates to constructs to provide such CARs and methods for introducing such CARs into cells and expressing such CARs in cells comprising receptors of gamma delta (??) T cells and/or Natural Killer (NK) cells.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: February 6, 2024
    Inventors: Agapitos Patakas, Timothy London, Emilio Cosimo
  • Patent number: 11881286
    Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 23, 2024
    Assignee: GENENTECH, INC.
    Inventors: Akshata Ramrao Udyavar, Yulei Wang, Cleopatra Kozlowski
  • Patent number: 11866511
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 9, 2024
    Assignee: TigaTX, Inc.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers
  • Patent number: 11866476
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: January 9, 2024
    Assignee: Xilio Development, Inc.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Patent number: 11857601
    Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: January 2, 2024
    Assignee: GI INNOVATION, INC.
    Inventors: Myung Ho Jang, Su Youn Nam, Young Jun Koh
  • Patent number: 11845792
    Abstract: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: December 19, 2023
    Assignee: University of Southern California
    Inventors: Parkash Gill, Ren Liu, Amy Lee
  • Patent number: 11839644
    Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 12, 2023
    Inventors: Michael P. Jankowski, Xiaohua Liu, John Barns Rose
  • Patent number: 11834492
    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: December 5, 2023
    Assignee: EPICENTRX, INC.
    Inventors: Christopher Larson, Tony R. Reid, Bryan T. Oronsky